News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Raffaele Colombo highlights FDA Breakthrough Device Designation for Roche’s TROP2 diagnostic assay
Raffaele Colombo/LinkedIn
May 4, 2025, 03:18

Raffaele Colombo highlights FDA Breakthrough Device Designation for Roche’s TROP2 diagnostic assay

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X by Stephen V Liu, adding:

“Based on AstraZeneca’s QCS for TROP2,
Roche Diagnostics received FDA Breakthrough Device Designation (BDD) for the VENTANA TROP2 (EPR20043) RxDx assay!
Nice spotlight presentation at AACR25.”

Read more about Roche’s FDA Breakthrough Device Designation for AI-driven NSCLC diagnostic here.

Raffaele Colombo

Quoting Stephen V Liu‘s post:

“Dr. Marina Garassino at WCLC24 Presidential Plenary presents Normalized Membrane Ratio of TROP2 as a biomarker for datopotamab deruxtecan in TROPION-Lung01 (Dato-DXd vs docetaxel in previously treated NSCLC which previously showed PFS benefit with Dato-DXd.“

Stephen V Liu

Learn more about Raffaele Colombo and TROPION-Lung01 on OncoDaily. 

AACR AACR25 AstraZeneca Breakthrough Device Designation cancer Dato-DXd datopotamab deruxtecan FDA Marina Garassino Medicine at Georgetown University NSCLC OncoDaily Oncology Roche Diagnostics Stephen V Liu TROP2 TROPION-Lung01 VENTANA TROP2 WCLC24 Zymeworks
Special Coverage
Blog
Jul 6, 2025, 02:27
A Public Hearing to Better Meet the Needs of Underserved Communities - European Cancer Organisation
Insight
Jul 5, 2025, 20:31
Diego A. Díaz García: Subclonal Immune Evasion in NSCLC
Blog
Jul 5, 2025, 20:15
Petros Grivas is Receiving 2025 Young Investigator Award
Blog
Jul 5, 2025, 20:00
Roberto Ferrara: Winter of Cancer Immunotherapy is Here
Blog
Jul 5, 2025, 19:42
Mario Balsa: TIME May Not Just Tell the Story - It Could Write the Prognosis STAR-01 at ESMOGI25
Blog
Jul 5, 2025, 19:18
Amol Akhade: CRC Screening Face-Off: Stool vs Blood
Blog
Jul 5, 2025, 18:53
Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options
Blog
Jul 5, 2025, 18:52
Saddened to Announce the Passing of Dr. Samantha Garza
Blog
Jul 5, 2025, 18:44
Because in a World Full of Opportunities, There’s No Time to Stop - CancerWorld
Blog
Jul 5, 2025, 18:38
Wongel Tsegaye: Crafting African Solutions for African Challenges
Blog
Jul 5, 2025, 18:26
Francisco J. Esteva: My New YouTube Channel Translates Breakthrough Cancer Care Into Plain, Evidence-based Guidance
Blog
Jul 5, 2025, 18:18
Don't Miss Out on the 2nd National Cancer Summit - National Cancer Institute of Kenya